Investigating The Potential for Immunotherapies in Diffuse Intrinsic Pontine Glioma (DIPG)


  • Anika Verma Saratoga High School
  • Alexander Wesolowski Saratoga High School



Immunotherapies, Diffuse Intrinsic Pontine Glioma, Biomedical Science, Cancer


Cancer is the second leading cause of death worldwide, and has significant economic, social, and emotional effects. Diffuse Intrinsic Pontine Glioma (DIPG), a rare type of cancer, is a devastating pediatric brain tumor that currently has no effective therapy. This disease affects around 150 to 300 children in the United States every year and poses a greater than 98 percent mortality rate within five years of diagnosis. DIPG has been suggested as a potential candidate for immunotherapies and this report’s main focus is on exploring immunotherapies as a treatment for DIPG. It first dives into the impact of cancer on society, introduces DIPG, and explores its biology and prevalence. It then explains the current treatment options, roadblocks, and advantages of immunotherapies over other diseases. This paper concludes by suggesting three most promising immunotherapies for the treatment of DIPG based on their effectiveness in similar brain cancers: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapy.


Download data is not yet available.

Author Biography

Alexander Wesolowski, Saratoga High School


References or Bibliography

World Health Organization. Cancer

National Cancer Institute. What Is Cancer?

American Cancer Society | Cancer Facts & Statistics

Cancer Facts & Figures 2022| American Cancer Society

Srikanthan, D.; Taccone, M. S.; Van Ommeren, R.; Ishida, J.; Krumholtz, S. L.; Rutka, J. T. Diffuse Intrinsic Pontine Glioma: Current Insights and Future Directions. Chinese Neurosurgical Journal 2021, 7 (1).

Organization, A. C. C. What Is a DIPG Brain Tumor?

Childhood Diffuse Intrinsic Pontine Glioma - Dana-Farber Cancer Institute | Boston, MA

High Grade Gliomas (accessed Mar 21, 2022).

DIPG Statistics Mar 21, 2022).

DIPG Survival Rate and Prognosis (accessed Mar 21, 2022).

Bernstein, S. DIPG: Rare Brain Tumor in Kids (accessed Mar 21, 2022).

Kergrohen, T. Copy-number alterations reshape the classification of diffuse intrinsic pontine gliomas. First exome sequencing results of the BIOMEDE trial

Chromothripsis (accessed Mar 21, 2022).

Buczkowicz, P.; Hoeman, C.; Rakopoulos, P.; Pajovic, S.; Letourneau, L.; Dzamba, M.; Morrison, A.; Lewis, P.; Bouffet, E.; Bartels, U.; Zuccaro, J.; Agnihotri, S.; Ryall, S.; Barszczyk, M.; Chornenkyy, Y.; Bourgey, M.; Bourque, G.; Montpetit, A.; Cordero, F.; Castelo-Branco, P. Genomic Analysis of Diffuse Intrinsic Pontine Gliomas Identifies Three Molecular Subgroups and Recurrent Activating ACVR1 Mutations. Nature genetics 2014, 46 (5), 451–456.

Zhang, Y.; Zhang, Z. The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and Their Therapeutic Implications. Cellular & Molecular Immunology 2020, 1–15.

What Is Immunotherapy? | Immunotherapy for Cancer (accessed Mar 21, 2022).

Waldman, A. D.; Fritz, J. M.; Lenardo, M. J. A Guide to Cancer Immunotherapy: From T-cell Basic Science to Clinical Practice. Nature Reviews Immunology 2020, 20, 1–18.

Immunotherapy (Brain Tumor Vaccine)| Brain Tumor Program | UCI Health | UCI Health | Orange County, CA (accessed Mar 21, 2022).

McCluskey, K. Immunotherapy vs. Chemotherapy: What’s the Difference?

Reck, M.; Rodríguez-Abreu, D.; Robinson, A. G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; O’Brien, M.; Rao, S.; Hotta, K.; Leiby, M. A.; Lubiniecki, G. M.; Shentu, Y.; Rangwala, R.; Brahmer, J. R. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine 2016, 375 (19), 1823–1833.

Portell, C. How Does CAR T-Cell Therapy Work in Treating Cancer?

Velcheti, V.; Schalper, K. Basic Overview of Current Immunotherapy Approaches in Cancer. American Society of Clinical Oncology Educational Book 2016, 36 (36), 298–308.

Raymond, J. Immunotherapy: How It Works for Cancer

Yang, T.; Kong, Z.; Ma, W. PD-1/PD-L1 Immune Checkpoint Inhibitors in Glioblastoma: Clinical Studies, Challenges and Potential. Human Vaccines & Immunotherapeutics 2020, 17 (2), 546–553.

Jiang, Y.; Chen, M.; Nie, H.; Yuan, Y. PD-1 and PD-L1 in Cancer Immunotherapy: Clinical Implications and Future Considerations. Human Vaccines & Immunotherapeutics 2019, 15 (5), 1111–1122.

Lei, Q. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors (accessed Mar 20, 2022).

Shirinbak, S.; Chan, R. Y.; Shahani, S.; Muthugounder, S.; Kennedy, R.; Hung, L. T.; Fernandez, G. E.; Hadjidaniel, M. D.; Moghimi, B.; Sheard, M. A.; Epstein, A. L.; Fabbri, M.; Shimada, H.; Asgharzadeh, S. Combined Immune Checkpoint Blockade Increases CD8+CD28+PD-1+ Effector T-cells and Provides a Therapeutic Strategy for Patients with Neuroblastoma. OncoImmunology 2021, 10 (1).

What are Cancer Vaccines?

Cancer Vaccines and Their Side Effects

Velcheti, V.; Schalper, K. Basic Overview of Current Immunotherapy Approaches in Cancer. American Society of Clinical Oncology Educational Book 2016, 36 (36), 298–308.

Xu, L. W.; Chow, K. K. H.; Lim, M.; Li, G. Current Vaccine Trials in Glioblastoma: A Review. Journal of Immunology Research 2014, 2014, e796856.

Pollack, I. F.; Jakacki, R. I.; Butterfield, L. H.; Okada, H. Ependymomas: Development of Immunotherapeutic Strategies. Expert Review of Neurotherapeutics 2013, 13 (10), 1089–1098.

John, P. CAR T-cell Therapy for Pediatric Brain Tumors (accessed Mar 20, 2022).

Portell, C. How Does CAR T-Cell Therapy Work in Treating Cancer?

Chmielewski, M. Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T-cells (accessed Mar 20, 2022).

Wang, J. Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma (accessed Mar 20, 2022).

Choi, B. D.; Maus, M. V.; June, C. H.; Sampson, J. H. Immunotherapy for Glioblastoma: Adoptive T-Cell Strategies. Clinical Cancer Research 2019, 25 (7), 2042–2048.

E.M. Veldhuijzen van Zanten, S. Validate User (accessed Mar 21, 2022).

Three things you need to know about CAR T-cell therapy (accessed Mar 21, 2022).

Holohan, M. Why pediatric cancers receive just 4% of cancer funding

Ventola, C. L. Cancer Immunotherapy, Part 3: Challenges and Future Trends. Pharmacy and Therapeutics 2017, 42 (8), 514–521.



How to Cite

Verma, A., & Wesolowski, A. . (2022). Investigating The Potential for Immunotherapies in Diffuse Intrinsic Pontine Glioma (DIPG) . Journal of Student Research, 11(2).



HS Review Articles